Browse Trials

➤

Find Breast Cancer Clinical Trials That Are Right For You

The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.

Use the search box and filters to find a trial that’s right for you.

Currently viewing trials
(Last updated: April 22, 2026)

and or

Reset

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

All U.S.

Early stage

Advanced

Treatment

Non-treatment

Phase I II III

Display Only New Trials

AKT

ALK

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

dMMR/MSI-H

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

ROS1

TP53

Click here to view online studies and trials that do not require site visits

NEAREST SITE: 2 miles
Zuckerberg San Francisco General
San Francisco,CA

VISITS: Up to 2 to 4 times per month for 1 year

PHASE: NA

NCT ID: NCT05297734

Supportive Cancer Care Delivered Virtually or by a Health Worker for Stage 0-IV Breast Cancer

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer Scientific Title

Purpose

To compare a technology-based supportive cancer care approach with a team-based supportive cancer care approach.

Who is this for?

People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV breast cancer that is newly diagnosed or whose cancer has come back. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational materials, virtual, weekly for 4 months, then every 2 weeks for 8 months</li> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 1 year</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational materials, in person or by phone, weekly for 4 months, then every 2 weeks for 8 months</li> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 1 year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The educational materials are designed to assist with advance care planning and symptom management. Topics include surrogate decision-makers, advance directives, and physician orders for life-sustaining treatment. The education is delivered to the participant by an electronic health record message or email, or by a lay health worker. </li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05297734' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 3 miles
UCSF Medical Center-Mission Bay
San Francisco,CA

VISITS: Please contact research site

PHASE: II

NCT ID: NCT05564377

ComboMATCH: Targeted Therapy Directed by Genetic Testing for Advanced Breast Cancer

Molecular Analysis for Combination Therapy Choice (ComboMATCH) Scientific Title

Purpose

To use genetic testing to match people to treatments and help doctors plan better treatments.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received at least 1 line of therapy for advanced disease or who have no standard treatment options available. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Targeted therapy based on genetic testing</li> </ul> Please contact research site for treatment schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic tests look at the unique genetic material (genes) of tumor cells.</li> <li class="seamTextUnorderedListItem">People with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: AKT, ERK, MEK, NF1, RAF, RAS</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05564377' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/press-releases/2023/combomatch-precision-medicine-cancer-initiative' target='_blank'>National Cancer Institute: ComboMATCH</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy' target='_blank'>Breastcancer.org: Targeted Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/precision-medicine-breast-cancer/about/pac-20385240' target='_blank'>Mayo Clinic: Precision Medicine for Breast Cancer</a> </li></ul>

NEAREST SITE: 3 miles
University of California San Francisco (UCSF)
San Francisco,CA

VISITS: 1 visit every week for 3-6 months

PHASE: II

NCT ID: NCT01042379

I-SPY 2: Personalized Treatment Before Surgery for Stage II-III Breast Cancer

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of standard of care therapy compared to standard of care therapy with an experimental drug chosen based on your tumor's biomarkers.

Who is this for?

People with stage II or stage III breast cancer who have not yet received treatment and whose cancer is high-risk for recurrence. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups and receive the following before surgery: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care therapy</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care therapy</li> <li class="seamTextUnorderedListItem">At least 1 experimental therapy chosen based on your tumor's biomarkers</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">4 MRIs</li> <li class="seamTextUnorderedListItem">2 biopsies</li> <li class="seamTextUnorderedListItem">Blood draws</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Targeted therapy is treatment specific to an individual's tumor type, which are called biomarkers.</li> <li class="seamTextUnorderedListItem">This clinical trial has an adaptive design. This means that experimental drugs will be added during the trial, and experimental drugs that are not more effective than standard of care therapy will be removed.</li> <li class="seamTextUnorderedListItem">At least 80% of people who enroll will receive an experimental drug.</li> <li class="seamTextUnorderedListItem">All drugs will be given before surgery (neoadjuvant therapy). This allows researchers to see how your tumor is responding to the drugs.</li> <li class="seamTextUnorderedListItem">For this trial, cancer is considered high-risk for recurrence if it tests MammaPrint Low (only if your tumor is ER- or ER+, HER2+) or MammaPrint High.</li> <li class="seamTextUnorderedListItem">MammaPrint is a genomic test that identifies genes in your tumor and gives two types of recurrence risk scores: low risk or high risk.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01042379' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ispypatient.org/' target='_blank'>Quantum Leap Healthcare Collaborative: I-SPY Patient Website</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/mammaprint-test' target='_blank'>Breastcancer.org: MammaPrint</a> </li><li class='seamTextUnorderedListItem'><a href='https://pubmed.ncbi.nlm.nih.gov/32701140/' target='_blank'>Journal Article: Three-Year Follow-Up Analysis for the I-SPY 2 Adaptively Randomized Clinical Trial</a> </li></ul>

NEAREST SITE: 61 miles
Stockton Hematology Oncology Medical Group
Stockton,CA

VISITS: Up to 2 years

PHASE: NA

NCT ID: NCT06272864

Genomic Test Studying the Tumor Microenvironment for Advanced Breast Cancer

BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting Scientific Title

Purpose

To study the ability of the BostonGene Tumor Portrait test to provide information about tumors and their microenvironment and help make treatment decisions.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy, blood, saliva, and cheek swab samples for the BostonGene Tumor Portrait test</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The tumor microenvironment describes the cells that surround a tumor and plays a role in both how tumors grow and how they respond to treatment. </li> <li class="seamTextUnorderedListItem">The BostonGene Tumor Portrait test may help make treatment decisions for people with advanced cancer.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06272864' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/breast-cancer-and-tumor-microenvironment/' target='_blank'>Metastatic Trial Talk: The Tumor Microenvironment</a> </li></ul>

NEAREST SITE: 336 miles
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05978128

Increasing Breast Cancer Screening Using Advocates and Supporters

Utilizing Spheres of Influence to Increase Cancer Screening: Empowering Community Health Advocates Scientific Title

Purpose

To investigate why some people may receive breast cancer screening but not lung cancer screening and to determine if advocates and supporters can increase screening.

Who is this for?

People at least 40 years old who do not currently have cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Access to online educational materials, 3 times within 2 years</li> <li class="seamTextUnorderedListItem">Meet with a patient navigator</li> <li class="seamTextUnorderedListItem">Education materials to share with friends/family on benefits of breast cancer screening</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer screening with mammography is widely accepted and commonly used.</li> <li class="seamTextUnorderedListItem">Advocates and supporters of lung cancer screening may increase the willingness to receive this screening.</li> <li class="seamTextUnorderedListItem">This trial also includes lung cancer screening.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05978128' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 348 miles
USC/Norris Comprehensive Cancer Center
Los Angeles,CA

VISITS: 1 visit every 6 months (coincides with standard follow up visits), for up to 7 years

PHASE: II

NCT ID: NCT04567420

A ctDNA Blood Test to Screen for Recurrence for Stage II-III ER+, HER2- Breast Cancer

A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer Scientific Title

Purpose

To study the anti-cancer activity, safety, and side effects of using a ctDNA blood test to guide treatment decisions in people who are taking anti-hormone therapy after surgery.

Who is this for?

People with stage II or stage III estrogen-receptor positive (ER+), HER2-negative (HER2-) breast cancer. You must be taking hormone therapy after surgery for at least the last 6 months. Your cancer must be considered at high risk for recurrence (coming back). See below for the definition of high-risk. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ctDNA blood test, every 4 to 6 months, for up to 7 years</li> </ul> If a ctDNA blood test is positive, you will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, monthly, ongoing</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your current anti-hormone therapy (an aromatase inhibitor or tamoxifen)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small bits of cancer cell DNA that specific tests can find in the bloodstream. </li> <li class="seamTextUnorderedListItem">Researchers are studying if a test looking for ctDNA in the bloodstream can determine if there will be a recurrence (coming back) of a person's breast cancer. </li> <li class="seamTextUnorderedListItem">The ctDNA blood test used in this trial is called Signatera. </li> <li class="seamTextUnorderedListItem">This trial is also studying if a recurrence can be stopped or delayed by giving people with a positive ctDNA test additional treatment.</li> <li class="seamTextUnorderedListItem">The additional treatment in this trial includes Palbociclib (Ibrance®) and Fulvestrant (Faslodex®).</li> <li class="seamTextUnorderedListItem">Palbociclib is commonly used with anti-estrogen therapy for metastatic, hormone-positive (ER+ and/or PR+), HER2-negative (HER2-) breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Fulvestrant is a type of anti-estrogen therapy called a SERD (selective estrogen receptor degrader). It is approved to treat some people with advanced HR+ breast cancer.</li> <li class="seamTextUnorderedListItem">For this trial, some of the definitions of cancer at high risk of recurrence include: </li> <li class="seamTextUnorderedListItem">Cancer found in 4 or more lymph nodes, or </li> <li class="seamTextUnorderedListItem">A tumor 5 cm or larger, or</li> <li class="seamTextUnorderedListItem">Cancer found in 1 to 3 lymph nodes, and your tumor was at least 3 cm, or grade 3 or, your Oncotype DX score was greater than 26, MammaPrint score was high risk, EndoPredict was greater than 4, or Prosigna score was greater than 60.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04567420' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/genetics/understanding/testing/circulatingtumordna/' target='_blank'>What is Circulating Tumor DNA and How is it Used to Diagnose and Manage Cancer?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.natera.com/oncology/signatera-advanced-cancer-detection/' target='_blank'>Natera ctDNA Test Information Page: Signature</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/issues/january-25-2021/a-tale-of-two-cdk46-inhibitors-in-early-breast-cancer/' target='_blank'>The ASCO Post: A Tale of Two CDK4/6 Inhibitors in Early Breast Cancer</a> </li></ul>

NEAREST SITE: 353 miles
City of Hope Comprehensive Cancer Center
Duarte,CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT06311214

Biomarker Testing to Select an Antibody-Drug Conjugate for Advanced Breast Cancer

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH) Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of using biomarkers to select an antibody-drug conjugate (ADC).

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer who have had a type of blood test called an RNA test. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 3 groups depending on your RNA blood test and biopsy results: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV, weekly, 2 weeks on 1 week off</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Biopsy, two times</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Enfortumab vedotin (Padcev®), by IV, weekly, 3 weeks on 1 week off</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Biopsy, two times</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Echocardiography or multigated acquisition scan (heart scans), 2 times</li> <li class="seamTextUnorderedListItem">Biopsy, two times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is testing the person's blood and tumor for the presence of the biomarkers, TROP-2, nectin 4, or HER2 to match them to one of three ADCs.</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a TROP-2-targeted ADC approved for triple-negative or HR+, HER2- MBC.</li> <li class="seamTextUnorderedListItem">Enfortumab vedotin (Padcev®) is a nectin4-targeted ADC approved for use in other cancers. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is a HER2-targeted ADC approved for HER2+ or HER2-low MBC.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06311214' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.trodelvy.com/?utm_source=google&utm_medium=cpc&utm_campaign=us_sem_trmd_onc_dtp_ex_mtnbc_go_na_na_b_standard_branded_1432nn&utm_content=17054576844%3B136230621779%3Bkwd-946345024054&utm_term=trodelvy&gclsrc=aw.ds&gad_source=1&gad_campaignid=17' target='_blank'>Gilead: Sacituzumab Govitecan (Trodelvy®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.padcev.com/' target='_blank'>Astellas Pharma: Enfortumab Vedotin (Padcev®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://enhertu.com/en/mbc?utm_source=google&utm_medium=cpc&utm_term=trastuzumab%20deruxtecan&utm_campaign=|CN|DTCB|BR|mBC|ENH|AZ|Core|Alone&utm_source=google&utm_medium=cpc&utm_campaign=%7CCN%7CDTCB%7CBR%7CmBC%7CENH%7CAZ%7CCore%7CAlone&utm_content=Alone%' target='_blank'>Daiichi Sankyo: Trastuzumab Deruxtecan (Enhertu®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates (ADCs)</a> </li></ul>

NEAREST SITE: 602 miles
Huntsman Cancer Institute at University of Utah
Salt Lake City,UT

VISITS: Coincides with surgery

PHASE: II

NCT ID: NCT05464082

Predict, Prevent, and Treat Early Metastatic Recurrence of HR Low, HER2-/HER2 Low or Triple Negative Breast Cancer

Towards Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of Triple Negative Breast Cancer Scientific Title

Purpose

To study ways to predict, prevent, and treat early metastatic recurrence.

Who is this for?

People with stage I, stage II, or stage III hormone receptor (ER and/or PR) low, HER2 negative (HER2-) or HER2 low or triple negative (ER-, PR-, HER2-) breast cancer. You must have not yet received treatment and be planning to receive surgery and chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples</li> <li class="seamTextUnorderedListItem">Blood tests</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Precision oncology is treatment based on specific information from your tumor.</li> <li class="seamTextUnorderedListItem">The tumor samples will be used to complete tests to determine which treatments may be most effective.</li> <li class="seamTextUnorderedListItem">If your cancer comes back (recurrence) after surgery and chemotherapy, your doctor will receive information to help make treatment decisions.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+ and ISH-.</li> <li class="seamTextUnorderedListItem">In this trial, hormone receptor (HR) low is defined as 1-10% of cells that are ER+ and PR+.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05464082' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/precision-medicine-breast-cancer/about/pac-20385240' target='_blank'>Mayo Clinic: What is Precision Oncology?</a> </li></ul>

NEAREST SITE: 660 miles
Mayo Clinic in Arizona
Scottsdale,AZ

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06055881

Radiation to Delay Treatment Changes and CTCs to Guide Treatment Options for People with Metastatic Breast Cancer

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS) Scientific Title

Purpose

To study if radiation therapy can delay treatment changes and if circulating tumor cells (CTCs) can help guide treatment options.

Who is this for?

Women with stage IV (metastatic) breast cancer who have been receiving their first line of therapy for metastatic disease for at least 1 year or have been receiving their second or later line of therapy for at least 6 months. You must have 1-3 sites of oligoprogressive disease that have not received radiation and must not have triple negative breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (also called stereotactic radiosurgery or stereotactic body radiotherapy) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li> <li class="seamTextUnorderedListItem">In this trial, CTCs may be used to help you and your doctor guide treatment options.</li> <li class="seamTextUnorderedListItem">Oligoprogressive disease refers to progression of only a few sites of metastasis.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06055881' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20555625' target='_blank'>Mayo Clinic: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/sbrt/pyc-20446794' target='_blank'>Mayo Clinic: Stereotactic Body Radiotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20071218' target='_blank'>Breastcancer.org: Circulating Tumor Cells</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oligometastatic-breast-cancer/' target='_blank'>Metastatic Trial Talk: What is Oligometastatic Breast Cancer?</a> </li></ul>

NEAREST SITE: 660 miles
Mayo Clinic in Arizona
Scottsdale,AZ

VISITS: Number of visits unavailable, up to 5 years

PHASE: II

NCT ID: NCT06525766

Changing the Dose of Capecitabine According to Scans to Control Metastatic ER+, HER2- Breast Cancer

Single Arm Pilot Trial of Adaptive Therapy (AT) With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, Hormone Refractory Breast Cancer Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of changing the dose of capecitabine (Xeloda®) chemotherapy according to the results of scans.

Who is this for?

People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer. You must not have received chemotherapy or fam-trastuzumab deruxtecan-nxki (Enhertu®), sacituzumab govitecan-hziy (Trodelvy®), or datopotamab deruxtecan (Dato-DXd; Datroway®) for your metastatic breast cancer. You must not have uncontrolled brain metastases. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth</li> <li class="seamTextUnorderedListItem">Bone scan</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy commonly used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Changing the dose of capecitabine (Xeloda®) according to how the tumor is growing on a scan may allow someone to live longer. This is called <q>adaptive therapy</q>. The goal of adaptive therapy is not to get rid of the entire tumor but to control its growth in a way that helps the patient live longer with a better quality of life.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06525766' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 682 miles
University of Washington
Seattle,WA

VISITS: 4 visits

PHASE: NA

NCT ID: NCT05704062

MRI Scans to Predict and Evaluate Response to Chemotherapy Before Surgery for People with Stage I-III Breast Cancer

Multi-Functional Magnetic Resonance Imaging Modalities for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy Scientific Title

Purpose

To study if MRI scans can earlier and more accurately predict and evaluate response to neoadjuvant (before surgery) chemotherapy.

Who is this for?

People with stage I, stage II, or stage III breast cancer who are planning to receive neoadjuvant (before surgery) chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scans, 4 times over the course of chemotherapy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment, like chemotherapy, before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies. </li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan is a type of scan that uses a very strong magnet and no radiation or x-ray energy to take very detailed pictures of parts of the body.</li> <li class="seamTextUnorderedListItem">MRI scans are often used as standard of care to take pictures of breast tumor(s) before and after chemotherapy treatment to measure the tumor size changes in response to treatment and plan for surgery.</li> <li class="seamTextUnorderedListItem">MRI scans are used because the images it takes are very clear and the borders of the tumor can be measured very accurately. However the tumor size alone is often not a good early indicator of whether or not the tumor responds to treatment.</li> <li class="seamTextUnorderedListItem">You will receive 4 MRI scans: before treatment, after the first treatment cycle, midway through treatment, and at the end of treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05704062' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-mri' target='_blank'>Breastcancer.org: Breast MRI</a> </li></ul>

NEAREST SITE: 682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle,WA

VISITS: 5 visits within 6 months or 1 year

PHASE: I-II

NCT ID: NCT06502691

[18F]FTT Radiotracer to Detect Response to PARP Inhibitors on a PET Scan for Metastatic Breast Cancer

[18F]FTT Positron Emission Tomography (PET) in Patients With Metastatic Breast Cancer Scientific Title

Purpose

To study how well fluorine F 18 fluorthanatrace ([18F]FTT) radiotracer works in a PET scan to detect the response to PARP inhibitors.

Who is this for?

People with metastatic (stage IV) breast cancer who are planning to receive olaparib (Lynparza®) or talazoparib (Talzenna®) PARP inhibitor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06502691' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 941 miles
Universtiy of Colorado Hospital
Aurora,CO

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06813053

Tool to Make Surgery Decisions for Women with Stage 0-III Breast Cancer

A Novel Decision Aid for Early Stage Breast Cancer Patients Choosing Between Lumpectomy and Mastectomy: a Pilot Study Scientific Title

Purpose

To study the use of a tool to help people with breast cancer make decisions about surgery.

Who is this for?

Women with newly diagnosed stage 0 (DCIS), stage I, stage II, or some stage III breast cancer who have not yet received surgery. You must not be planning to receive chemotherapy before surgery (neoadjuvant). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Decision tool, by email</li> <li class="seamTextUnorderedListItem">Interview</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational information about surgical options for breast cancer, by email</li> <li class="seamTextUnorderedListItem">Interview</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The decision tool is designed to help improve shared decision-making by explaining the risks and benefits of surgery options according to your personal values and preferences.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06813053' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1382 miles
Mercy Hospital - OKC
Oklahoma City,OK

VISITS: Coincides with biopsy

PHASE: NA

NCT ID: NCT07327489

Liver Biopsy to Predict Response to Immunotherapy for Metastatic Breast Cancer That has Spread to the Liver

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies Scientific Title

Purpose

To collect liver tumor samples to study a possible response to immunotherapy.

Who is this for?

People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer that has spread to the liver. You must have not yet started your next line of therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Liver biopsy as part of standard of care</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is collecting samples of breast cancer that has spread to the liver to understand ways to prepare the tissue to predict how a patient may respond to immunotherapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07327489' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1509 miles
UT Southwestern Medical Center
Dallas,TX

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT05693766

Hormone Therapy or Chemotherapy with Genetic Testing for Metastatic HR+, HER2- Breast Cancer

Integrating Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT) Scientific Title

Purpose

To compare the safety, effects (good and bad), and anti-cancer activity of hormone therapy and capecitabine (Xeloda®) chemotherapy and use MammaPrint® and BluePrint tests to guide treatment decisions.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received treatment with hormone therapy and a CDK4/6 inhibitor. You must not have received chemotherapy or more than 1 line of hormone therapy for advanced disease or have a PIK3CA mutation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of hormone therapy</li> <li class="seamTextUnorderedListItem">Provide tissue samples for MammaPrint® and BluePrint tests </li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 1 week on, 1 week off</li> <li class="seamTextUnorderedListItem">Provide tissue samples for MammaPrint® and BluePrint tests</li> </ul> Please contact research site for treatment schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy drug commonly used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">MammaPrint® and BluePrint are genetic tests that use tumor samples to help guide treatment decisions.</li> <li class="seamTextUnorderedListItem">The tests will also be used to determine if certain mutations are potentially associated with resistance to therapy.</li> <li class="seamTextUnorderedListItem">This trial is for people with non-Luminal A breast cancer. Luminal A breast cancer is ER+, PR+, and HER2- with low Ki-67 levels, which controls how fast cancer cells grow. Luminal A cancers tend to grow more slowly.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05693766' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/xeloda' target='_blank'>Breastcancer.org: Capecitabine (Xeloda®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/mammaprint-test' target='_blank'>Breastcancer.org: MammaPrint®</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/molecular-subtypes' target='_blank'>Breastcancer.org: Molecular Subtypes of Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/genetic-testing' target='_blank'>Breastcancer.org: Genetic Testing for Breast Cancer</a> </li></ul>

NEAREST SITE: 1509 miles
UT Southwestern/Simmons Cancer Center-Dallas
Dallas,TX

VISITS: 4 visits

PHASE: II-III

NCT ID: NCT04715958

Ultrasound Scans to Predict Response to Chemotherapy Before Surgery for Stage I-III Breast Cancer

Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation Scientific Title

Purpose

To study if ultrasound scans with perflutren (Definity®), an experimental contrast dye, can predict response to chemotherapy.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy before surgery (neoadjuvant). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasound scan with perflutren (Definity®), by IV, 3 times</li> <li class="seamTextUnorderedListItem">Utrasound scan, 4 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Perflutren (Definity®) is an experimental contrast dye used to create better images during ultrasounds. </li> <li class="seamTextUnorderedListItem">The ability of cancer treatment to work is affected by the pressure in the cancer.</li> <li class="seamTextUnorderedListItem">Ultrasound scans use sound waves to produce images of structures within your body.</li> <li class="seamTextUnorderedListItem">The ultrasound scan in this trial, contrast-enhanced ultrasound, may be able to detect pressures in cancer and therefore predict response to chemotherapy before surgery (neoadjuvant).</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04715958' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit

PHASE: NA

NCT ID: NCT02918474

A Tool to Help Women Decide Whether to Have a Contralateral Preventative Mastectomy

Decision Making Tool for Contralateral Prophylactic Mastectomy Scientific Title

Purpose

To learn more about an online decision support tool that helps you and your doctor discuss whether or not you should have a contralateral prophylactic mastectomy (removal of breast that does not have cancer).

Who is this for?

Women recently diagnosed with DCIS or stage I, stage II, or stage III breast cancer and are seeing a surgeon at MD Anderson Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete a questionnaire before and after using the decision support tool.
If you take part in this study, you will complete a questionnaire about the decision support tool.
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02918474' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1678 miles
University of Wisconsin Carbone Cancer Center
Madison,WI

VISITS: 1 visit every 3 to 4 weeks, ongoing

PHASE: I

NCT ID: NCT04174352

Imaging to Personalize Amount of Tamoxifen in Advanced, ER+, HER2- Breast Cancer With a ESR1 Mutation

A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 Mutations Scientific Title

Purpose

To study if FES-PET/CT scans can help find a personalized dose of tamoxifen (Nolvadex®).

Who is this for?

People with advanced (some stage III) or metastatic (stage IV), estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer that tests positive for a ESR1 mutation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">FES PET/CT scan, every 3 to 4 weeks, ongoing</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is an anti-estrogen therapy used to treat hormone-sensitive breast cancer.</li> <li class="seamTextUnorderedListItem">ESR1 mutations in breast cancer may affect how well tamoxifen works against tumor cells. </li> <li class="seamTextUnorderedListItem">Tracers are chemicals that are used to find cancer cells in the body during a PET scan. The imaging trial will use the tracer fluoroestradiol (FES)--it finds estrogen receptors in breast tumors. </li> <li class="seamTextUnorderedListItem">The FES tracer may also show how tamoxifen is affecting your tumors. Researchers may use this information to increase your dose of tamoxifen.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ESR1</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04174352' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/hormonal-therapy-metastatic-breast-cancer' target='_blank'>ASCO Cancer.net: Hormonal Therapy for Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal/serms/tamoxifen' target='_blank'>Breastcancer.org: Tamoxifen</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/more-effective-therapies-needed-for-patients-with-esr1mutated-breast-cancer' target='_blank'>Targeted Oncology: More Effective Therapies Needed For Patients With ESR1-Mutated Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.karger.com/Article/FullText/481428' target='_blank'>Journal Article: Are We Ready to Use ESR1 Mutations in Clinical Practice</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ijcem.com/files/ijcem0076055.pdf' target='_blank'>Journal Article: The Role of PET Imaging Probes for Early Monitoring the Response to Tamoxifen</a> </li></ul>

NEAREST SITE: 1737 miles
Siteman Cancer Center
St Louis,MO

VISITS: 2 visits within 2 months

PHASE: NA

NCT ID: NCT03524430

RDA Test to Determine Response to Treatment Before Surgery for Stage I-III Breast Cancer

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY) Scientific Title

Purpose

To study how well the RNA Disruption Assay (RDA) test can predict response to treatment during neoadjuvant (before surgery) treatment.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive neoadjuvant (before surgery) chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy, 2 times within 2 months</li> <li class="seamTextUnorderedListItem">RNA Disruption Assay (RDA) test using biopsy samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tests that can predict who will respond and who will not respond to chemotherapy early during treatment are important for the best outcomes.</li> <li class="seamTextUnorderedListItem">The RNA Disruption Assay (RDA) test uses a biopsy sample to test for a biomarker that tells doctors whether chemotherapy is killing cancer cells.</li> <li class="seamTextUnorderedListItem">If the RDA test tells the doctor that chemotherapy is not working, the doctor may consider switching your treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03524430' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://rnadiagnostics.com/rda/' target='_blank'>RNA Diagnostics: The RDA Test</a> </li></ul>

NEAREST SITE: 1739 miles
Washington University School of Medicine
St Louis,MO

VISITS: At least 4 visits within 4 months

PHASE: NA

NCT ID: NCT05977036

Biomarker Test to Change or Continue Treatment for Advanced HR+, HER2- Breast Cancer

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer Scientific Title

Purpose

To use the DiviTum® TKa blood test to determine if people with advanced HR+, HER2- breast cancer should continue or switch treatments.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have not yet received treatment for advanced disease. You must be planning to receive hormone therapy with a CDK4/6 inhibitor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups depending on results of the DiviTum® TKa blood tests: Group 1: Suppressed (Low) TKa Levels <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DiviTum® TKa blood test, 4 times within 4 months</li> <li class="seamTextUnorderedListItem">Continue on endocrine therapy and CDK4/6 inhibitor (i.e., Ribociclib)</li> <li class="seamTextUnorderedListItem">Imaging scans</li> </ul> Group 2: Unsuppressed (Not Low) TKa Levels <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DiviTum® TKa blood test, 4 times within 4 months</li> <li class="seamTextUnorderedListItem">Switch treatment</li> <li class="seamTextUnorderedListItem">Imaging scans</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DiviTum® TKa blood test is a blood test that measures thymidine kinase activity (TKa) which may predict how well tumors respond to treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05977036' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://biovica.com/divitum/' target='_blank'>Biovica: DiviTum® Test</a> </li></ul>

NEAREST SITE: 1739 miles
Washington University School of Medicine
St Louis,MO

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT05837455

Biomarkers to Guide Therapy Before Surgery for Stage II-III ER+, HER2- Breast Cancer

NeoTAILOR: A Phase II Biomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer Scientific Title

Purpose

To study the effects (good and bad) of whether a novel biomarker-driven approach can be used to guide selection of treatment before surgery (neoadjuvant).

Who is this for?

Postmenopausal women with newly diagnosed stage II or stage III estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast MRI scan, 2 times</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Biomarker tests</li> <li class="seamTextUnorderedListItem">Surgery</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast MRI scan, 2 times</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Biopsy</li> <li class="seamTextUnorderedListItem">Biomarker tests</li> <li class="seamTextUnorderedListItem">Surgery</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast MRI scan, 2 times</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®), by mouth, daily for 1 month</li> <li class="seamTextUnorderedListItem">Biopsy</li> <li class="seamTextUnorderedListItem">Biomarker tests</li> <li class="seamTextUnorderedListItem">Chemotherapy with an anthracycline drug, by IV, and/or a taxane, by IV, for up to 6 months</li> <li class="seamTextUnorderedListItem">Surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarkers are genes, molecules, or other features present in a person that tell doctors something about that person’s health.</li> <li class="seamTextUnorderedListItem">Using biomarkers to select treatment may improve the clinical response and identify those who may not require chemotherapy before surgery (neoadjuvant).</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05837455' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1761 miles
University of Wisconsin School of Medicine and Public Health
Madison,WI

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04573231

Evaluating PSMA Expression to Determine Response to Anti-Androgen Therapies for Metastatic HER2-, AR+ Breast Cancer

Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT Scientific Title

Purpose

To evaluate prostate specific membrane antigen (PSMA) expression in breast cancer to determine people most likely to benefit from anti-androgen therapies.

Who is this for?

People with metastatic (stage IV) HER2 negative (HER2-), androgen receptor positive (AR+) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 18F-DCFPyL</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTC) test</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Prostate specific membrane antigen (PSMA) expression may correlate with resistance to anti-androgen therapies, which has been documented in prostate cancer.</li> <li class="seamTextUnorderedListItem">Evaluating PSMA expression may be used to select people most likely to benefit from anti-androgen therapies, such as bicalutamide (Casodex®), in future clinical trials.</li> <li class="seamTextUnorderedListItem">18F-DCFPyL is a tracer that is used to visualize PSMA expression during imaging scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are breast cancer cells that leave the tumor and move through the bloodstream.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PSMA, AR</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04573231' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/news/psma-new-target-prostate-cancer-treatment' target='_blank'>Memorial Sloan Kettering Cancer Center: PSMA</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/#:~:text=A%20circulating%20tumor%20cell%20(CTC,test%20for%20metastatic%20breast%20cancer.' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li></ul>

NEAREST SITE: 1849 miles
Orchard Healthcare Research Inc.
Skokie,IL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05935384

Guardant360 Blood Test to Measure Treatment Response for People with Advanced Breast Cancer

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation Scientific Title

Purpose

To collect information to develop a Guardant360 blood test that can measure treatment response.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) who have received 0-1 lines of therapy for advanced disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guardant360 blood test</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guardant360 is a blood test that identifies genomic biomarkers and mutations to help make treatment decisions.</li> <li class="seamTextUnorderedListItem">This trial is collecting information to develop a future version of Guardant360 that can measure treatment response.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05935384' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/tumor-marker-tests' target='_blank'>Breastcancer.org: Breast Cancer Biomarkers and Biomarker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://guardanthealth.com/products/tests-for-patients-with-advanced-cancer/' target='_blank'>Guardant Health: Guardant360 Test Information Page</a> </li></ul>

NEAREST SITE: 1851 miles
Pennington Biomedical Research Center
Baton Rouge,LA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06318507

Studying Gut Bacteria After Immunotherapy in People with Stage I-III Triple Negative Breast Cancer

The Intestinal Microbiome in Triple Negative Breast Cancer Treated With Immunotherapy (IMPACT) Scientific Title

Purpose

To study how bacteria in the gut are different between women with stage I-III triple negative breast cancer who are obese and respond to immunotherapy compared to women who do not respond to immunotherapy.

Who is this for?

Women with newly diagnosed stage I, stage II, or stage III triple negative (ER-, PR-, HER2-) breast cancer who are overweight or obese (BMI 25+) and have not yet received treatment. You must be planning to receive neoadjuvant (before surgery) pembrolizumab (Keytruda®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stool (poop) sample</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immunotherapy drugs trigger the immune system to see, go after, and kill cancer cells.</li> <li class="seamTextUnorderedListItem">The microbiome consists of the many bacteria, viruses, and fungi found on your body.</li> <li class="seamTextUnorderedListItem">The harmful bacteria cause disease such as infection, and the beneficial bacteria help keep you healthy.</li> <li class="seamTextUnorderedListItem">Bacteria in the gut may also play a role in whether or not someone responds to immunotherapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06318507' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1958 miles
Vanderbilt University/Ingram Cancer Center
Nashville,TN

VISITS: Coincides with routine care

PHASE: II

NCT ID: NCT05770531

ctDNA Tests to Support Treatment Decisions for People with Metastatic Triple Negative, PD-L1 Negative Breast Cancer

A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast Cancer Scientific Title

Purpose

To study how well circulating tumor DNA (ctDNA) tests work to support decisions to change treatment.

Who is this for?

People with metastatic (stage IV) triple negative (ER-, PR-, HER2-), PD-L1 negative breast cancer who have not received chemotherapy for metastatic disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care chemotherapy</li> <li class="seamTextUnorderedListItem">Blood samples for ctDNA tests</li> <li class="seamTextUnorderedListItem">CT scan or MRI scan, 2 times</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care chemotherapy</li> <li class="seamTextUnorderedListItem">Blood samples for ctDNA tests</li> <li class="seamTextUnorderedListItem">CT scan or MRI scan, 2 times</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Switch to sacituzumab govitecan (Trodelvy®), by IV (depending on blood test results)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small bits of cancer cell DNA that specific tests can find in the bloodstream.</li> <li class="seamTextUnorderedListItem">Studying ctDNA may help your doctor decide to change your treatment earlier (if needed) and may improve your health outcomes.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05770531' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/trodelvy' target='_blank'>Breastcancer.org: Sacituzumab Govitecan (Trodelvy®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/ctdna-mbc/' target='_blank'>Metastatic Trial Talk: The Latest Research on ctDNA and MBC</a> </li></ul>

NEAREST SITE: 1984 miles
University of Louisville Hospital
Louisville,KY

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT07044557

Surgery for Breast Cancer that has Spread to the Brain Without Dexamethasone

MeDex: No Perioperative Dexamethasone in Brain Metastases Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of surgery for brain metastasis without dexamethasone before, during, or up to 3 weeks after surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). The cancer in your brain must have been recently diagnosed, and you must be planning to receive brain surgery to remove the cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove the tumor</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone is a steroid used during brain surgery to prevent brain swelling. Because it is an anti-inflammatory drug, it may also reduce the effect of immunotherapies used to treat cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07044557' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1985 miles
Baptist Health Clinical Research
Elizabethtown,KY

VISITS: At least 2 visits over 6-8 weeks

PHASE: NA

NCT ID: NCT05037825

How the Gut Microbiome May Affect Immunotherapy in Stage I-IV Triple Negative Breast Cancer

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors Scientific Title

Purpose

To study the gut microbiome to see if it can determine if immunotherapy will be effective.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) triple negative breast cancer (ER-, PR- and HER2-) who are about to begin treatment with a checkpoint inhibitor (immunotherapy). You must speak English or Spanish. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">2 blood tests over 6-8 weeks</li> <li class="seamTextUnorderedListItem">2 stool samples over 6-8 weeks</li> <li class="seamTextUnorderedListItem">Questionairres (in English or Spanish)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The microbiome may help determine if immunotherapy will be effective. </li> <li class="seamTextUnorderedListItem">By studying the microbiome, researchers may also be able to determine if changing the microbiome through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, can help the immune system fight cancer.</li> <li class="seamTextUnorderedListItem">Immunotherapies are drugs that trigger the immune system to see, go after, and kill cancer cells. </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) and atezolizumab (Tecentriq®) are a type of immunotherapy called a PD-1 inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05037825' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2013 miles
The University of Alabama at Birmingham
Birmingham,AL

VISITS: 3-4 visits

PHASE: I

NCT ID: NCT04332588

PET/MRI Scans to Monitor Response to Trastuzumab (Herceptin®) for Women with Stage II-III HER2+ Breast Cancer

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI Scientific Title

Purpose

To determine if PET/MRI scans with 18F-FMISO can help monitor and predict the effect of trastuzumab (Herceptin®).

Who is this for?

Women with newly diagnosed stage II or stage III HER2 positive (HER2+) breast cancer who have not yet received treatment and are planning to receive trastuzumab (Herceptin®) before surgery (neoadjuvant). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/MRI scan with 18F-FMISO and gadoteridol (Prohance®), by IV, 2-3 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">18F-FMISO is an experimental imaging tracer for use in PET/MRI scans.</li> <li class="seamTextUnorderedListItem">Gadoteridol (Prohance®) is a standard of care imaging contrast agent for use in PET/MRI scans.</li> <li class="seamTextUnorderedListItem">The results of this study will not change your treatment plan, but it may help doctors and researchers better understand how best to treat people with breast cancer in the future.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04332588' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2054 miles
University of Michigan Comprehensive Cancer Center
Ann Arbor,MI

VISITS: Monthly for 6 months

PHASE: II

NCT ID: NCT07158021

Leuprolide or Goserelin to Reduce Estrogen for Pre- or Peri-Menopausal Women With Stage I-IV Breast Cancer

Phase 2 Randomized Trial to Examine Ovarian Function Suppression for Breast Cancer (OFS) Scientific Title

Purpose

To compare a low dose of leuprolide (Lupron®), a high dose of leuprolide (Lupron®), and goserelin (Zoladex®) for their ability to reduce estrogen production.

Who is this for?

Pre-menopausal or peri-menopausal women with stage I, stage II, stage III, or stage IV (metastatic) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to receive a gonadotropin releasing hormone (GnRH) agonist plus hormone therapy. You must have completed chemotherapy if recommended. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leuprolide (Lupron®), low dose, by injection, monthly for 6 months</li> <li class="seamTextUnorderedListItem">Blood tests</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leuprolide (Lupron®), high dose, by injection, monthly for 6 months</li> <li class="seamTextUnorderedListItem">Blood tests</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®), by injection, monthly for 6 months</li> <li class="seamTextUnorderedListItem">Blood tests</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leuprolide (Lupron®) and goserelin (Zoladex®) are given to pre-menopausal and peri-menopausal women with HR+ breast cancer. These drugs block the ability of the ovaries to make estrogen, which causes HR+ breast cancer to grow.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07158021' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zoladex.com/?gclsrc=aw.ds&gad_source=1&gad_campaignid=22507845007&gbraid=0AAAAA_gRoNBb5XSY7s8DD7IIxTBZtXTv6&gclid=Cj0KCQiAoZDJBhC0ARIsAERP-F-ABUsC3lGhM3VH4Nc4qtBUZY8e6bBS1dm4GjfxXphAdMMFnwMJfWgaAkRAEALw_wcB' target='_blank'>AstraZeneca: Goserelin (Zoladex®)</a> </li></ul>

NEAREST SITE: 2108 miles
Mount Carmel West Hospital
Columbus,OH

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT03536897

Radiation During Breast Cancer Surgery in Women Age 65 and Older

Intraoperative Radiation Therapy (IORT) Following Breast Conserving Surgery for Early Stage Breast Cancer Registry Scientific Title

Purpose

To develop a registry that will allow researchers to study the 5-year risk of a local breast cancer recurrence after intraoperative radiation therapy (IORT).

Who is this for?

Women age 65 or older with stage II or stage III low- risk breast cancer who will be treated with partial mastectomy (lumpectomy) and radiation during surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IORT (Intraoperative radiation), during surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Intraoperative radiation therapy (IORT) is given right after the tumor has been removed while you are still in the operating room.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03536897' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/intraoperative-radiation-therapy/about/pac-20385150' target='_blank'>Mayo Clinic: Intraoperative radiation therapy (IORT)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tricitymed.org/2016/10/iort-breast-cancer-treatment-primer/' target='_blank'>Tricity Medicine: IORT as Breast Cancer Treatment: A Primer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.uptodate.com/contents/overview-of-the-approach-to-early-breast-cancer-in-older-women' target='_blank'>UpToDate: Overview of the approach to early breast cancer in older women</a> </li></ul>

NEAREST SITE: 2264 miles
Magee Women's Hospital of UPMC
Pittsburgh,PA

VISITS: 4 visits in 3 months

PHASE: NA

NCT ID: NCT06666439

Liquid Biopsy to Monitor Treatment Response for Women with Metastatic Lobular ER+ Breast Cancer

LBC-Monitor: Liquid Biopsy Guided Tailoring of Therapy in Metastatic Lobular Breast Cancer (mILC): a Pilot Study of Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA Scientific Title

Purpose

To study how circulating tumor DNA (ctDNA) changes over time to help monitor treatment response and make treatment decisions.

Who is this for?

Women with metastatic (stage IV) estrogen receptor positive (ER+) or ER low, HER2 negative (HER2-) lobular breast cancer who have not yet received treatment for metastatic disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests, 4 times in 3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lobular breast cancer can be difficult to see and monitor on scans.</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">A ctDNA test is sometimes called a liquid biopsy.</li> <li class="seamTextUnorderedListItem">ctDNA tests may improve the ability to monitor treatment response in lobular breast cancer and identify changes in the tumor cells that may predict resistance to hormone therapy.</li> <li class="seamTextUnorderedListItem">This information may allow doctors to change treatments when it is most beneficial to patients.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06666439' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2264 miles
University of Pittsburgh Medical Center
Pittsburgh,PA

VISITS: 3 visits within 1 year

PHASE: NA

NCT ID: NCT07262138

Regular Ultrasound Scans for Older Women With Stage I ER+ Breast Cancer

Protocol-Directed Active Surveillance for Older Women With Small, Screen-Detected, ER+/HER2- Breast Cancer Scientific Title

Purpose

To study if active surveillance (regular imaging rather than treatment) is a safe approach to monitor small breast cancers.

Who is this for?

Women, aged 70 years or older, with newly diagnosed stage I estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer that was detected on a mammogram who have not received treatment for their breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast ultrasound scan, 3 times within 1 year</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nearly one-third of all breast cancer cases are diagnosed in patients older than 70 years. Overdiagnosis, which is detection of cancers that would never have caused symptoms or affected lifespan, can occur in older people. Overdiagnosis can create anxiety and reduce quality of life.</li> <li class="seamTextUnorderedListItem">Active monitoring may be better than treatment for managing small breast cancers in older women.</li> <li class="seamTextUnorderedListItem">Participants in this study may receive more frequent imaging.</li> <li class="seamTextUnorderedListItem">If a patient's tumor progresses, she may begin to receive treatment as recommended by her care team.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07262138' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2299 miles
Roswell Park Cancer Institute
Buffalo,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04526587

Studying Response to Treatment With CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors Scientific Title

Purpose

To study how breast cancer develops resistance to treatment with CDK 4/6 inhibitors and how to predict response to treatment with CDK 4/6 inhibitors.

Who is this for?

People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer or people with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) node positive breast cancer. You must have completed treatment with or currently be receiving treatment with a CDK 4/6 inhibitor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood, tissue, fluid, and biopsy samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your samples may be used to help your doctor make treatment decisions.</li> <li class="seamTextUnorderedListItem">Node positive breast cancer is breast cancer that has spread to the lymph nodes.</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04526587' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK 4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/?utm_medium=email&utm_source=subscribers&utm_campaign=Dec2022&utm_content=Email122022' target='_blank'>Metastatic Trial Search: CDK Inhibitors</a> </li></ul>

NEAREST SITE: 2371 miles
University of Virginia
Charlottesville,VA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT06507618

Hormone Therapy Before Lumpectomy to Help Make Radiation Decisions for Older Women with Stage I-III ER+, HER2- Breast Cancer

A Randomized, Phase III Trial of Pre-Operative Window of Endocrine Therapy to Inform Radiation Therapy Decisions in Older Women With Early-Stage Breast Cancer (POWER II) Scientific Title

Purpose

To study if hormone therapy before lumpectomy helps older women make decisions about receiving radiation.

Who is this for?

Women at least 65 years old with stage I, stage II, or stage III estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who are planning to receive a lumpectomy. You must not have cancer in your lymph nodes. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Hormone Therapy and Lumpectomy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hormone therapy, by mouth, 3 months</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumpectomy</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Lumpectomy Only <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumpectomy</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The standard of care treatment for stage I-III ER+ breast cancer is lumpectomy (also called breast conserving surgery), radiation, and then 5-10 years of hormone therapy.</li> <li class="seamTextUnorderedListItem">Radiation is sometimes not needed for women 65 years or older. </li> <li class="seamTextUnorderedListItem">Hormone therapy is needed but sometimes not completed because of side effects.</li> <li class="seamTextUnorderedListItem">A previous study showed that taking hormone therapy for 3 months before lumpectomy helped with decision-making about omitting radiation and continuing to receive hormone therapy after surgery.</li> <li class="seamTextUnorderedListItem">In this trial, the hormone therapy drugs are tamoxifen (Nolvadex®), letrozole (Femara®), anastrozole (Arimidex®), or exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06507618' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2382 miles
UNC Lineberger Comprehensive Cancer Center
Chapel Hill,NC

VISITS: 8 visits during treatment, then 1 visit every 3 months, up to 3 years

PHASE: II

NCT ID: NCT07069595

PREDICT-RD: Using ctDNA to Detect Triple Negative Breast Cancer After Surgery

PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC With Residual Disease Scientific Title

Purpose

To use circulating tumor DNA (ctDNA) to detect cancer cells after surgery and to determine who will or will not receive benefit from Dato-DXd (a targeted therapy).

Who is this for?

People with stage II or stage III triple negative (ER- or ER low, PR- or PR low, HER2-) breast cancer who have residual disease after neoadjuvant (before surgery) chemotherapy and surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) blood test at the time of surgery, every 6 weeks during treatment, then every 3 months, ongoing, up to 3 years</li> </ul> Positive ctDNA test at the time of surgery: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd), by IV, 8 times</li> </ul> Negative ctDNA test at the time of surgery: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care adjuvant (after surgery) treatment</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Residual disease refers to cancer cells present after treatment.</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small bits of cancer cell DNA that specific tests can find in the bloodstream.</li> <li class="seamTextUnorderedListItem">ctDNA tests are also called liquid biopsies.</li> <li class="seamTextUnorderedListItem">In this study, changes in ctDNA in the blood will be monitored during treatment, and for up to 3 years after completing treatment.</li> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd) is an investigational antibody-drug conjugate (ADC) and a TROP2 (topoisomerase I) targeted therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07069595' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/liquid-biopsy/' target='_blank'>Metastatic Trial Talk: Understanding Liquid Biopsies for MBC</a> </li></ul>

NEAREST SITE: 2383 miles
Mayo Clinic Florida
Jacksonville,FL

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT03823144

Studying Tumor Blood Flow to Make Treatment Decisions for People with Stage 0-IV Breast Cancer

Intravital Microscopy (IVM) in Human Solid Tumors Scientific Title

Purpose

To use Human Intravital Microscopy (HIVM) to study tumor blood flow and gather information to make treatment decisions.

Who is this for?

People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Human Intravital Microscopy (HIVM) with fluorescein, by IV, during surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Human Intravital Microscopy (HIVM) is a procedure completed during surgery to study tumor blood vessels and blood flow.</li> <li class="seamTextUnorderedListItem">IVM can determine if your blood vessels work well enough to be able to receive some types of cancer treatment.</li> <li class="seamTextUnorderedListItem">Fluorescein is used during HIVM to see how blood flows.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03823144' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/what-is-cancer/body-systems-and-cancer/cancer-the-blood-and-circulation' target='_blank'>Cancer Research UK: Cancer and Blood Circulation</a> </li></ul>

NEAREST SITE: 2385 miles
Duke Cancer Institute
Durham,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06275126

Online Tool for Making Surgery Decisions for Young Women With Stage 0-III Breast Cancer

Optimizing Surgical Decisions in Young Adults With Breast Cancer (CONSYDER) Scientific Title

Purpose

To understand and improve the breast surgery decision-making process for young women newly diagnosed with breast cancer.

Who is this for?

Women up to 44 years old with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have not yet received surgery. Your breast cancer must not have recurred (come back). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

Based on when you enroll, you will take part in 1 of 2 groups: Group 1: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Surveys, 2-3 times within 6 months</li> <li class="seamTextUnorderedListItem">Interview, 1 time (optional)</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Access to online CONSYDER decision tool</li> <li class="seamTextUnorderedListItem">Surveys, 2-3 times within 6 months</li> <li class="seamTextUnorderedListItem">Interview, 1 time (optional)</li> </ul> People in Group 1 will have access to the online CONSYDER decision tool after 6 months.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CONSYDER is an online tool that is designed to provide useful information to young people with breast cancer. </li> <li class="seamTextUnorderedListItem">CONSYDER was also designed to improve communication between young women and their surgeons with the purpose of helping patients make surgical decisions.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06275126' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2402 miles
UNC Rex Healthcare
Raleigh,NC

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03769415

HARMONY: Using a Genomic Test to Guide Treatment Decisions for Metastatic Breast Cancer

HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer Scientific Title

Purpose

To study if genomic testing affects which line of therapy doctors suggest people with metastatic breast cancer receive.

Who is this for?

People with metastatic (stage IV) breast cancer who have received no more than one line of therapy for metastatic disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PAM50 (Prosigna®) testing of your breast tumor, 1 time</li> <li class="seamTextUnorderedListItem">Results of the PAM50 test will be given to your treating doctor</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The standard of care for treating metastatic breast cancer is to make treatment decisions based on clinical subtype. </li> <li class="seamTextUnorderedListItem">Clinical subtypes include hormone-positive (ER+ and/or PR+), HER2-positive (HER2+), and triple-negative (ER-, PR-, HER2-).</li> <li class="seamTextUnorderedListItem">The PAM50 (Prosigna®) is a genomic test approved for use in some women with early-stage breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Genomic testing looks at genetic mutations within your tumor. This gives your doctor a genetic subtype of your tumor. </li> <li class="seamTextUnorderedListItem">This trial is studying whether knowing a tumor's genetic subtype will affect how doctors treat people with metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">Making treatment decisions based on genetic subtypes is not the standard of care.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03769415' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://unclineberger.org/octr/our-team/' target='_blank'>Study Coordinator Information: Terri Eubanks</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/genomic-tumor-testing/' target='_blank'>Metastatic Trial Talk: Genomic Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prosigna.com' target='_blank'>Veracyte Test Information Page: PAM50 (Prosigna®)</a> </li></ul>

NEAREST SITE: 2406 miles
The University of North Carolina
Chapel Hill,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06817226

Designing a Breast Reconstruction Decision Making Tool for Latinx Women

Cultural and Linguistic Adaptation of a Breast Reconstruction Decision Tool (BREASTChoice) Scientific Title

Purpose

To study the best cultural and language options for making the BREASTChoice decision aid available in Spanish.

Who is this for?

Latina/Latinx women who have stage 0 (DCIS), stage I, stage II, or some stage III breast cancer or are at high risk for breast cancer and received a mastectomy in the last 8 years. You must prefer to speak Spanish at home. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BREASTChoice decision aid</li> <li class="seamTextUnorderedListItem">Interviews</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast reconstruction can improve quality of life and body image after mastectomy.</li> <li class="seamTextUnorderedListItem">Spanish speaking Latinx people are less likely to undergo reconstruction, meet with a reconstructive surgeon, or receive enough information.</li> <li class="seamTextUnorderedListItem">BREASTChoice is a tool that helps people make decisions about breast reconstruction.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06817226' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2406 miles
Lineberger Comprehensive Cancer Center, University of North Carolina
Chapel Hill,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06896162

Increasing Biomarker-Informed Treatment for Metastatic Breast Cancer

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival Scientific Title

Purpose

To study whether intervention from a navigator and expert review of results of DNA analysis by a pharmacist will increase ordering of biomarker-informed therapy compared to an estimated historical rate of 15% and enrollment in biomarker-informed clinical trials.

Who is this for?

People with stage IV (metastatic) breast cancer for whom biomarker testing is considered appropriate but who have not received it. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood or tissue samples</li> <li class="seamTextUnorderedListItem">Review of your biomarker results by an expert</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarkers are genes, molecules, or other features present in a person that tell doctors something about that person’s health.</li> <li class="seamTextUnorderedListItem">Patients with cancer have better outcomes when their treatments are selected with the help of biomarker testing. However, genomic testing, which is a type of biomarker testing, is not used as often as it should be.</li> <li class="seamTextUnorderedListItem">This trial is studying whether making biomarker test ordering and interpretation easier for clinicians will increase the rate of biomarker-informed treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06896162' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/new-biomarkers/' target='_blank'>Metastatic Trial Talk: Biomarkers for Selection of MBC Treatment</a> </li></ul>

NEAREST SITE: 2427 miles
Advent Winter Garden
Winter Garden,FL

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT06572410

Lumpectomy with EnVisio Navigation System for Women with Stage 0-III Breast Cancer

Prospective Analysis of EnVisio Spatial Intelligence for Soft Tissue Localization and Guided Surgical Excision Scientific Title

Purpose

To study the ability of a lumpectomy with the EnVisio Surgical Navigation system to result in a negative margin.

Who is this for?

Women with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer who are planning to receive a lumpectomy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumpectomy with the EnVisio Navigation System</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The EnVisio Surgical Navigation system may allow precise removal of breast tumors and result in a negative margin.</li> <li class="seamTextUnorderedListItem">A negative margin is the presence of a border of healthy tissue around the tumor. Obtaining a negative margin increases the likelihood that all cancer cells were removed during surgery.</li> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06572410' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT07067138

Set of Rules (Algorithm) to Find Therapeutic Options for Triple Negative or HR+, HER2- Metastatic Breast Cancer

An Exploratory Study Using a Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) Scientific Title

Purpose

To study whether a set of rules (an algorithm) called ENLIGHT can help choose approved drugs that will treat aggressive breast cancers more effectively.

Who is this for?

People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer. You must have received at least one line of therapy, be planning to stop your current therapy due to progression of your cancer or side effects, and be not eligible for another treatment. If HR+, your cancer must be resistant to hormone therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor analyzed by ENLIGHT, TruSight(R) Oncology 500, and TruSeq</li> <li class="seamTextUnorderedListItem">No therapy match, treatment selected by doctor</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Biopsy after treatment (optional)</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor analyzed by ENLIGHT, TruSight(R) Oncology 500, and TruSeq</li> <li class="seamTextUnorderedListItem">Treatment with matched, approved drug for participant's cancer, given by participant's doctor</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Biopsy after treatment (optional)</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor analyzed by ENLIGHT, TruSight(R) Oncology 500, and TruSeq</li> <li class="seamTextUnorderedListItem">Treatment with matched drug approved for another use, given by doctors at NIH</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Biopsy after treatment (optional)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized medicine currently selects only a small subgroup of patients by looking for direct matches between their cancer and treatments. This trial is testing a way of identifying more patients who may benefit from targeted therapies.</li> <li class="seamTextUnorderedListItem">ENLIGHT analyzes tumor tissue and may be useful for identifying therapeutic options for people with metastatic breast cancer who currently have limited treatment options.</li> <li class="seamTextUnorderedListItem">The TruSight and TruSeq tests look for biomarkers in tumor tissue and blood that match a person to an approved treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07067138' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/new-biomarkers/' target='_blank'>Metastatic Trial Talk: Biomarkers to Select Treatments for MBC</a> </li></ul>

NEAREST SITE: 2434 miles
Medstar Georgetown University Hospital
Washington D.C.,DC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05334732

Sisters Informing Sisters Coaching Program to Improve Treatment Adherence in Black Women with Stage I-III Breast Cancer

Improving Communication and Adherence in Black Breast Cancer Survivors Scientific Title

Purpose

To study if the Sisters Informing Sisters coaching program increases adherence to treatment.

Who is this for?

Black women with newly diagnosed stage I, stage II, or stage III breast cancer who received surgery less than 1 month ago and are planning to begin chemotherapy or hormone therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sisters Informing Sisters coaching program</li> <li class="seamTextUnorderedListItem">Workbook </li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">National Cancer Institute treatment information booklet</li> </ul> Please contact research site for trial schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sisters Informing Sisters is a peer-based, culturally-tailored, positive role-modeling coaching program.</li> <li class="seamTextUnorderedListItem">In Sisters Informing Sisters, Black cancer survivors educate Black women with breast cancer about how to communicate with their doctors and the importance of completing treatment.</li> <li class="seamTextUnorderedListItem">The National Cancer Institute treatment information booklet provides women with national-level recommendations regarding treatment recommendations.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05334732' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://richmondmagazine.com/life-style/health/going-for-the-moon-shot/' target='_blank'>Richmond Magazine: Sisters Informing Sisters</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/latest-news/breast-cancer-death-rates-are-highest-for-black-women-again.html#:~:text=Black%20women%20have%20the%20lowest%205%2Dyear%20relative%20breast%20cancer,and%20every%20breast%20cancer%20subtype.&text=There%20is%20a%206%25%20t' target='_blank'>American Cancer Society: Black Women and Breast Cancer</a> </li></ul>

NEAREST SITE: 2517 miles
Abramson Cancer Center
Philadelphia,PA

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT05396612

Studying Immune Cell Response to Treatment for Women with Stage I-III ER+, HER2- Breast Cancer

Role of the Immune Environment in Response to Therapy in Breast Cancer Scientific Title

Purpose

To study differences in immune cells in different types of breast cancer.

Who is this for?

Women with stage I, stage II, or stage III estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who are planning to receive surgery at the University of Pennsylvania Health System. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue samples from surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immune system cells play an important role in finding and killing cancer cells.</li> <li class="seamTextUnorderedListItem">This study will compare immune system cells and their role in outcomes after treatment in different types of breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05396612' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge,NJ

VISITS: Coincides with surgery

PHASE: IV

NCT ID: NCT07308717

Mastectomy With or Without Gabapentin for Stage I-III Breast Cancer

Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol Scientific Title

Purpose

To study whether gabapentin (Neurontin®) should be a standard part of mastectomy pain control.

Who is this for?

People with stage I, stage II, or stage III breast cancer who are planning to receive a mastectomy at the Josie Robertson Surgical Center (New York or New Jersey). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gabapentin (Neurontin®) before surgery</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No gabapentin (Neurontin®) before surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gabapentin (Neurontin®) is used to treat nerve pain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07308717' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge
Basking Ridge,NJ

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT07335354

Decision Tool for Women With Stage 0-III Breast Cancer or Women at High Risk for Breast Cancer Considering Breast Reconstruction Surgery

Breast Reconstruction Decision Aid (RECONJOINT) Scientific Title

Purpose

To study the effectiveness of the Breast Reconstruction Decision Aid Tool called RECONJOINT for breast reconstruction surgery.

Who is this for?

Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer, or women at high risk for breast cancer, who are considering receiving a mastectomy followed by breast reconstruction. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Participate in focus group</li> <li class="seamTextUnorderedListItem">Usual care</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RECONJOINT</li> <li class="seamTextUnorderedListItem">Enhanced usual care</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RECONJOINT is a breast reconstruction decision aid.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07335354' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2541 miles
RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton
Hamilton,NJ

VISITS: Number of visits unavailable

PHASE: IV

NCT ID: NCT07158164

Dose Selection of Capecitabine or 5-Fluorouracil According to Genetic Testing for the DYPD Gene for Stage I-IV Breast Cancer

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment Scientific Title

Purpose

To study the safety and effects (good and bad) of 5-fluorouracil (5-FU) or capecitabine (Xeloda®) chemotherapy when the dose is selected based on testing of the DPYD gene.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive 5-fluorouracil (5-FU) or capecitabine (Xeloda®). You must have received DPYD genetic testing. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups, depending on your DPYD genetic testing results: Group 1: Normal DPYD Gene <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">5-fluorouracil (5-FU), by injection, standard dose OR </li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by injection, standard dose</li> <li class="seamTextUnorderedListItem">Dose will be reduced if needed</li> <li class="seamTextUnorderedListItem">Dose may be increased if tolerated</li> </ul> Group 2: DPYD Gene Variant <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">5-fluorouracil (5-FU), by injection, half the standard dose OR </li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by injection, half the standard dose</li> <li class="seamTextUnorderedListItem">Dose may be increased if tolerated</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">5-Fluorouracil (5-FU) and capecitabine (Xeloda®) are chemotherapy drugs commonly used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">People can respond differently to these drugs due to genetic variations. The FDA now recommends testing for these genetic variants.</li> <li class="seamTextUnorderedListItem">This trial will test dosing of these drugs guided by genetic testing.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07158164' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2561 miles
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale,NJ

VISITS: At least 4 visits within 1-2 months

PHASE: I-II

NCT ID: NCT05130801

Imaging Scans Before and During Surgery for Women with Stage 0-III Breast Cancer

Phase I/IIa Study of Pre-operative Multiparametric MRI and pHLIP® ICG Intra-operative Fluorescence Imaging of Primary Breast Cancer Scientific Title

Purpose

To study whether enhanced MRI scans before surgery and near infrared fluorescent (NIRF) imaging scans during surgery are safe and improve surgery outcomes.

Who is this for?

Women with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer who are planning to receive a lumpectomy. You must not have received treatment before surgery (neoadjuvant). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan, 1-3 weeks before surgery</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">pHLIP ICG tracer, by IV, at least 1 time before surgery</li> <li class="seamTextUnorderedListItem">NIRF imaging scan, during surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">An enhanced MRI scan before surgery may provide better information about the tumor and improve outcomes.</li> <li class="seamTextUnorderedListItem">A near infrared fluorescent (NIRF) imaging scan is a new type of imaging scan used to produce body pictures using infrared light.</li> <li class="seamTextUnorderedListItem">pHLIP ICG is an experimental tracer for NIRF imaging scans that may help locate cancer in the body.</li> <li class="seamTextUnorderedListItem">Near infrared fluorescent (NIRF) imaging scans during surgery may allow the surgeon to see the cancer cells more clearly and remove them completely.</li> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05130801' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2564 miles
University of Vermont Medical Center
Burlington,VT

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06280300

Multi-Disciplinary Care and Decision Making for People with Brain Metastases

Intensive Multi-Disciplinary Care Initiative for Patients With Newly Diagnosed Brain Metastases Scientific Title

Purpose

To compare how well multi-disciplinary care and standard care work for managing symptoms and understanding outcomes.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Your brain metastases must be newly diagnosed. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Multi-disciplinary care</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Care for people with brain metastases involves complex medical decision making and requires input for multiple groups (disciplines).</li> <li class="seamTextUnorderedListItem">Multi-disciplinary care includes medical oncology, neurosurgery, radiation oncology, neuro-oncology, and palliative care.</li> <li class="seamTextUnorderedListItem">This process may look different for different patients.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06280300' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2567 miles
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York,NY

VISITS: 2 visits within 2 weeks

PHASE: NA

NCT ID: NCT06127979

Studying Changes in Ki67 Expression Before and After Hormone Therapy for Women with Stage I-III ER+, HER2- Breast Cancer

Differential Changes in Ki67 Between Carriers and Noncarriers of BRCA2 Mutations With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer Treated With Preoperative Endocrine Therapy Scientific Title

Purpose

To study changes in Ki67 before and after hormone therapy, which may suggest response to treatment.

Who is this for?

Women with stage I, stage II, or stage III estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have not yet received surgery. You must not be planning to receive neoadjuvant (before surgery) chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy, before and during surgery</li> <li class="seamTextUnorderedListItem">Standard of care hormone therapy</li> <li class="seamTextUnorderedListItem">Blood tests</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ki67 is a protein found in cancer cells.</li> <li class="seamTextUnorderedListItem">By measuring the amount of the Ki67 protein in your cancer cells, researchers can learn how quickly the cancer cells are growing.</li> <li class="seamTextUnorderedListItem">The researchers are also looking at how Ki67 levels change in people with and without a mutation in BRCA2.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06127979' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2567 miles
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05559853

MRI Scan to Study Changes in Brain Tumors After Treatment

Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases Scientific Title

Purpose

To develop a new MRI scan technique that will study the difference between tumor growth from cancer progression and tumor growth from treatment side effects.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive stereotactic radiosurgery. You must have at least 1 brain tumor that has not received radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting</li> </ul> Please contact research site for treatment schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting is a type of MRI scan.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05559853' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2569 miles
Columbia University Irving Medical Center
New York,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05351424

Video or Brochure to Educate Non-English Speaking Latinx Women with Breast Cancer About Radiation Therapy and Cancer Clinical Trials

Audiovisual Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment (ADELANTE) Study in Radiation Oncology Scientific Title

Purpose

To develop educational materials to prepare Latinx Spanish-speaking people for radiation therapy and to improve understanding about participating in cancer clinical trials.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are Spanish speakers of Latinx background (from Mexican, Puerto Rican, Cuban, Dominican, Central or South American ancestry) and who are planning to receive radiation therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to Group 1 or 2: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch a video with educational information about radiation therapy.</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive a brochure with written information about radiation therapy.</li> </ul> You will also be randomly assigned to Group 3 or 4: Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch a video with educational information about cancer clinical trials.</li> </ul> Group 4 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive a brochure with written information about cancer clinical trials.</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low understanding of health information and language barriers can lead to low trial enrollment in minority and/or non-English speakers and produce trial results that don't reflect this population.</li> <li class="seamTextUnorderedListItem">Culturally appropriate audiovisual materials may improve knowledge about radiotherapy and increase chances of completing treatment, as well as improve knowledge about clinical trials and increase enrollment in Latinx/Spanish-speaking people.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05351424' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.astro.org/Patient-Care-and-Research/Provider-Resources/Patient-Brochures' target='_blank'>American Society for Radiation Oncology: Patient Brochures</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/patient-education/cancer-treatment-research-studies' target='_blank'>National Cancer Institute: Taking Part in Cancer Research Studies</a> </li></ul>

NEAREST SITE: 2569 miles
Herbert Irving Comprehensive Cancer Care Center
New York,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05146297

Clinical Trial Education and Navigation for People with Stage I-IV Breast Cancer

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials Scientific Title

Purpose

To study whether a list of clinical trials, clinical trial educational materials, and clinical trial patient navigators (CTPN) increase participation in clinical trials, especially in the Black, Indigenous, and People of Color (BIPOC) community.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">List of matched clinical trials</li> <li class="seamTextUnorderedListItem">Clinical trial educational materials</li> <li class="seamTextUnorderedListItem">Clinical trial patient navigator (CTPN)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive a list of matched clinical trials and educational materials designed to inform and empower you to consider clinical trials.</li> <li class="seamTextUnorderedListItem">You will also work with a clinical trial patient navigator (CTPN) to further educate you about clinical trials.</li> <li class="seamTextUnorderedListItem">This trial is available in English and Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05146297' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2574 miles
Montefiore Medical Center
The Bronx,NY

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03694756

Experimental Breast MRI Scan for People with Suspected Breast Cancer or Stage I-III Breast Cancer

TMEM-MRI: A Pilot Feasibility Study of Magnetic Resonance Imaging for Imaging of TMEM (Tumor Microenvironment of Metastasis) in Patients With Operable Breast Cancer Scientific Title

Purpose

To study the ability of TMEM-MRI, an experimental type of MRI scan, to detect breast cancer cells.

Who is this for?

People with a breast mass that is suspected to be breast cancer, or people with stage I, stage II, or some stage III breast cancer who have not yet received treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TMEM-MRI scan, 1 time</li> <li class="seamTextUnorderedListItem">Contrast agent, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Biopsy (if you have not yet received one)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Tumor Microenvironment of Metastasis - Magnetic Resonance Imaging (TMEM-MRI) scans are an experimental type of MRI scan that can detect tumor areas that are more likely to travel to other sites in the body.</li> <li class="seamTextUnorderedListItem">TMEM-MRI scans may be useful to identify tumors with a higher chance of coming back (recurrence) after treatment.</li> <li class="seamTextUnorderedListItem">TMEM-MRI scans may also be useful for studying the response to neoadjuvant (before surgery) treatment such as chemotherapy and hormone therapy.</li> <li class="seamTextUnorderedListItem">A contrast agent, also called a tracer, is a radioactive substance that can look for and attach to cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03694756' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-mri' target='_blank'>Breastcancer.org: Breast MRI</a> </li></ul>

NEAREST SITE: 2591 miles
University of Miami
Miami,FL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05959291

Free-HER: Stopping Maintenance Anti-HER2 Targeted Therapy for People with Metastatic HER2+ Breast Cancer and No Evidence of Disease

Free-HER: Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer Scientific Title

Purpose

To study if people who stop taking anti-HER2 targeted therapy for maintenance will stay in complete remission.

Who is this for?

People with metastatic (stage IV) HER2 positive (HER2+) breast cancer who have been in complete remission, also called no evidence of disease (NED), for at least 3 years and have been receiving anti-HER2 targeted therapy for at least 3 years. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stop taking anti-HER2 targeted therapy</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Imaging scans</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is a type of anti-HER2 targeted therapy commonly used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Complete remission is also known as no evidence of disease (NED).</li> <li class="seamTextUnorderedListItem">Blood tests will measure circulating tumor DNA (ctDNA), which are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">You will continue to receive routine monitoring, blood tests, and imaging scans.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05959291' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/herceptin' target='_blank'>Breastcancer.org: Trastuzumab (Herceptin®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/herceptin' target='_blank'>Breastcancer.org: What is Anti-HER2 Targeted Therapy?</a> </li></ul>

NEAREST SITE: 2614 miles
Yale University
New Haven,CT

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT06953882

Option to Omit Chemotherapy for Stage II-III ER+, HER2- Breast Cancer

SELECT: A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient's Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-Positive, HER2- Negative Breast Cancer With a Combination Regimen of Ribociclib and Optimized Endocrine Therapy Scientific Title

Purpose

To study whether choosing not to receive chemotherapy after surgery increases the chances of completing treatment with ribociclib (Kisqali®), a CDK 4/6 inhibitor.

Who is this for?

People with stage II or some stage III estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer with an Oncotype DX Recurrence Score ≤ 25 who are planning to receive ribociclib (Kisqali®) and hormone therapy. You must have received surgery and cancer was found in your lymph nodes. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will choose to be in 1 of 2 groups: Group 1: No chemotherapy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®), by mouth, daily, 3 weeks on 1 week off, for 1 year</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) or anastrozole (Arimidex®), by mouth, daily, for 1 year</li> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®) (if male or premenopausal female only), by injection, monthly, for 1 year</li> </ul> Group 2: With Chemotherapy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of chemotherapy, for 1 year</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®), by mouth, daily, 3 weeks on 1 week off, for 1 year</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) or anastrozole (Arimidex®), by mouth, daily, for 1 year</li> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®) (if male or premenopausal female only), by injection, monthly, for 1 year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In clinical trials, around one-third of patients stopped taking CDK 4/6 inhibitors before it was planned due to side effects.</li> <li class="seamTextUnorderedListItem">The OncotypeDx 21-gene Breast Recurrence Score Test is a biomarker test that predicts the benefit of chemotherapy in certain people with breast cancer.</li> <li class="seamTextUnorderedListItem">An OncotypeDx recurrence score of 0-25 indicates a less aggressive cancer that will not benefit from chemotherapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06953882' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-patients/test-results' target='_blank'>Exact Sciences: Oncotype DX Breast Recurrence Score Test</a> </li></ul>

NEAREST SITE: 2619 miles
Dartmouth Hitchcock Medical Center
Lebanon,NH

VISITS: 1 visit every month

PHASE: II

NCT ID: NCT05933395

Hormone Therapy and Targeted Therapy Based on Biomarker Testing for Advanced ER+, HER2- Breast Cancer

Genetically-informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: a Phase II Umbrella Study (GERTRUDE) Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of hormone therapy and targeted therapy based on biomarker testing.

Who is this for?

Post-menopausal women with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+) or ER low, HER2 negative (HER2-) or HER2 low breast cancer. You must have received treatment with palbociclib (Ibrance®), ribociclib (Kisqali®), or abemaciclib (Verzenio®) for advanced disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 4 groups based on biomarker testing results: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth, daily</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Everolimus (Afinitor®), by mouth, daily</li> </ul> Group 4 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive treatment based on ERBB2, PIK3CA, AKT1, MTOR, PTEN, and RB1 biomarker testing results.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is an anti-HER2 targeted therapy that stops cancer cells from growing by targeting and blocking the HER2 proteins that help cancer cells grow.</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) is a type of targeted therapy called a PI3K inhibitor. Blocking the PI3K pathway may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Everolimus (Afinitor®) is a type of targeted therapy called an mTOR inhibitor. It works by interfering with a cancer cell's ability to divide and grow.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK4/6 inhibitor. CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+/FISH -.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05933395' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/nerlynx' target='_blank'>Breastcancer.org: Neratinib (Nerlynx®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/piqray' target='_blank'>Breastcancer.org: Alpelisib (Piqray®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/afinitor' target='_blank'>Breastcancer.org: Everolimus (Afinitor®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/verzenio' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT03452774

Using Artificial Intelligence to Match Patients to Clinical Trials (SYNERGY-AI)

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry Scientific Title

Purpose

To study if a computer that has been taught how to match people to clinical trials (artificial intelligence) can help increase enrollment in clinical trials.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer who have already decided to enroll in a clinical trial. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A clinical trial matching report based on your medical records that you can review with your doctor.</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will use artificial intelligence and virtual tumor boards to help match people to clinical trials.</li> <li class="seamTextUnorderedListItem">The researchers will also create a registry to study the medical and financial effects of this program. </li> <li class="seamTextUnorderedListItem">This is an international trial that is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03452774' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://massivebio.com/' target='_blank'>Massive Bio Study Information Page</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT03448926

Impact of DCISionRT Test on Treatment Decisions for Women with DCIS and LCIS

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy (PREDICT) Scientific Title

Purpose

To study the impact of the DCISionRT test on treatment decisions for people with DCIS or LCIS.

Who is this for?

Women 30-85 years old with stage 0 (DCIS or LCIS) breast cancer who were diagnosed in the last 4 months and are planning to receive or have received a lumpectomy. You must have received the DCISionRT test. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide access to the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Health data</li> <li class="seamTextUnorderedListItem">Imaging data</li> <li class="seamTextUnorderedListItem">Tissue samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The DCISionRT test predicts the risk of recurrence over 10 years and the benefit from radiation therapy.</li> <li class="seamTextUnorderedListItem">Your doctor will complete surveys before and after receiving the DCISionRT test. The surveys will study how the DCISionRT test results were used to make treatment decisions.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03448926' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://preludedx.com/patients/' target='_blank'>PreludeDx: DCISionRT</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT06915168

Virtual Tool to Help Make Chemotherapy Decisions for People with Stage I-IV Breast Cancer

CIPN Decision Aid to Improve Neurotoxic Chemotherapy Decision Making Scientific Title

Purpose

To see if a virtual tool that informs people about chemotherapy-induced peripheral neuropathy (CIPN) helps people make decisions about chemotherapy.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving paclitaxel (Taxol®), nab-paclitaxel (Abraxane®), or docetaxel (Taxotere) chemotherapy and are experiencing peripheral neuropathy (nerve pain, discomfort, sensation changes, or weakness). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual chemotherapy decision tool</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neuropathy is pain, discomfort, sensation changes, and weakness from nerve damage.</li> <li class="seamTextUnorderedListItem">Chemotherapy-induced peripheral neuropathy (CIPN) is neuropathy in your hands and feet as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Around half of people who develop CIPN still have it 3 years later.</li> <li class="seamTextUnorderedListItem">A virtual decision tool that provides information about permanent CIPN and prepares patients for a discussion with their doctor may lead to improvements in treatment decision-making.</li> <li class="seamTextUnorderedListItem">This trial is enrolling virtually and does not require any in person visits.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06915168' target='_blank'>ClinicalTrials.gov</a> </li></ul>